Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2024, Vol. 44 Issue (1): 98-106    DOI: 10.13523/j.cb.2309023
综述     
MicroRNA调控在溶瘤病毒疗法中的应用与展望*
赵灿阳1(),林燕真2,程通3,王玮1,***()
1 厦门大学公共卫生学院 国家传染病诊断试剂与疫苗工程技术研究中心 厦门 361102
2 厦门大学附属中山医院 厦门 361004
3 厦门大学生命科学学院 厦门 361102
Application of MicroRNA Regulation in Oncolytic Virotherapy and Its Prospects
Canyang ZHAO1(),Yanzhen LIN2,Tong CHENG3,Wei WANG1,***()
1 National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Pulic Health,Xiamen University, Xiamen 361102, China
2 Affiliated Zhongshan Hospital, Xiamen University, Xiamen 361004, China
3 School of Life Sciences, Xiamen University, Xiamen 361102, China
 全文: PDF(1128 KB)   HTML
摘要：

MicroRNA(miRNA)是一类内源性的、能够特异性调控真核生物细胞内转录后基因表达的非编码单链RNA。近年来,miRNA的调控作用已被广泛应用于溶瘤病毒的设计。一方面,通过在病毒基因组中插入肿瘤内表达下调的组织特异性miRNA的靶序列,可以改变溶瘤病毒的组织趋向性,在达到减毒效果的同时保留其抗肿瘤活性。另一方面,通过在病毒基因组中插入表达天然或人工改造的miRNA,可以促进病毒复制,改善肿瘤微环境,从而增强溶瘤病毒的疗效。讨论目前miRNA调控在溶瘤病毒领域中的应用进展,为优化溶瘤病毒疗法策略提供参考。
关键词： MicroRNA;  溶瘤病毒;  靶向调控;  病毒治疗    
Abstract:

MicroRNAs (miRNAs) are a type of endogenous, non-coding, single-stranded RNA that specifically regulates post-transcriptional gene expression in eukaryotic cells. In recent years, miRNA regulation has been utilized in the design of oncolytic viruses. By inserting a target sequence of a tissue-specific miRNA that is down-regulated in the tumor into the viral genome, the tissue tropism of the oncolytic virus can be altered, and the anti-tumor activity of the virus can be remained during viral attenuation. Additionally, natural or artificially modified miRNAs can be inserted and expressed in viral genomes to promote viral replication and improve the tumor microenvironment, thereby enhancing the therapeutic effect of oncolytic viruses. This paper reviews and discusses the utilization of miRNA regulation in oncolytic virology, with the aim of providing insights into the optimization of existing oncolytic virotherapy strategies.
Key words: MicroRNA    Oncolytic virus    Targeted regulation    Virotherapy
收稿日期: 2023-09-20 出版日期: 2024-02-04
ZTFLH:  Q789  
基金资助: *福建省自然科学基金(2022J011352)
通讯作者: ***电子信箱:lukewang@xmu.edu.cn   
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
赵灿阳
林燕真
程通
王玮

引用本文:

赵灿阳, 林燕真, 程通, 王玮. MicroRNA调控在溶瘤病毒疗法中的应用与展望*[J]. 中国生物工程杂志, 2024, 44(1): 98-106.

Canyang ZHAO, Yanzhen LIN, Tong CHENG, Wei WANG. Application of MicroRNA Regulation in Oncolytic Virotherapy and Its Prospects. China Biotechnology, 2024, 44(1): 98-106.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2309023    或    https://manu60.magtech.com.cn/biotech/CN/Y2024/V44/I1/98

组织部位 miRNAs
血液 hsa-miR-486-5p、hsa-miR-451a、hsa-miR-92a-3p、hsa-miR-191-5p
骨骼 hsa-miR-10b-5p、hsa-miR-143-3p、hsa-miR-100-5p、hsa-let-7a-5p、hsa-miR-21-5p、hsa-miR-191-5p、hsa-miR-22-3p
心脏 hsa-miR-1-3p、hsa-miR-143-3p、hsa-miR-133a-3p、hsa-miR-27b-3p、hsa-miR-99a-5p
肝脏 hsa-miR-148a-3p、hsa-miR-22-3p、hsa-miR-122-5p、hsa-miR-143-3p、hsa-miR-21-5p、hsa-miR-192-5p、hsa-miR-101-3p、hsa-let-7a-5p、hsa-miR-10a-5p
肺 hsa-miR-143-3p、hsa-miR-21-5p、hsa-miR-30a-5p、hsa-miR-22-3p、hsa-miR-101-3p、hsa-miR-30a-3p、hsa-miR-10a-5p、hsa-let-7a-5p、hsa-miR-148a-3p、hsa-miR-99b-5p、hsa-let-7b-5p、hsa-miR-103a-3p
肾 hsa-miR-10b-5p、hsa-miR-30a-5p、hsa-miR-143-3p、hsa-miR-10a-5p、hsa-miR-22-3p、hsa-miR-30a-3p、hsa-miR-21-5p、hsa-let-7a-5p、hsa-miR-99b-5p、hsa-miR-26a-5p
胰腺 hsa-miR-21-5p、hsa-miR-143-3p、hsa-miR-22-3p、hsa-miR-148a-3p、hsa-let-7a-5p、hsa-miR-10a-5p、hsa-miR-375-3p、has-miR-216a/b、has-miR-217
大脑 hsa-miR-26a-5p、hsa-miR-181a-5p、hsa-let-7a-5p、hsa-miR-16-5p、hsa-miR-9-5p、hsa-miR-99a-5p、hsa-miR-143-3p、hsa-miR-100-5p、hsa-let-7f-5p、hsa-miR-27b-3p、hsa-miR-22-3p、hsa-miR-128-3p
结肠 hsa-miR-143-3p、hsa-miR-192-5p、hsa-miR-375-3p、hsa-miR-10b-5p、hsa-miR-10a-5p、hsa-let-7b-5p、hsa-miR-92a-3p、hsa-miR-99b-5p、hsa-miR-26a-5p、hsa-let-7a-5p
直肠 hsa-miR-143-3p、hsa-miR-192-5p、hsa-miR-10b-5p、hsa-miR-10a-5p、hsa-miR-21-5p、hsa-miR-26a-5p、hsa-let-7a-5p、hsa-miR-181a-5p
前列腺 hsa-miR-143-3p、hsa-miR-21-5p、hsa-miR-99a-5p、hsa-miR-148a-3p、hsa-miR-26a-5p
子宫内膜 hsa-miR-143-3p、hsa-miR-10b-5p、hsa-let-7a-5p、hsa-miR-21-5p、hsa-miR-10a-5p、hsa-let-7b-5p、hsa-miR-22-3p、hsa-miR-101-3p
膀胱 hsa-miR-143-3p、hsa-miR-21-5p、hsa-miR-22-3p、hsa-miR-10b-5p、hsa-let-7a-5p
肌肉 hsa-miR-1-3p、hsa-miR-133a-3p、hsa-miR-378a-3p、hsa-miR-143-3p、hsa-miR-26a-5p
表1  人体特定组织中富集的miRNA
肿瘤类型 表达下调的miRNA 表达上调的miRNA
头颈癌 miR-195-5p、miR-101-3p、miR-136-3p、miR-145-3p、miR-375 miR-615-3p、miR-503-3p、miR-21-5p、miR-455-3p、miR-93-5p
乳腺癌 Let-7-7c-5p、miR-1-3p、miR-30e-3p、miR-139-5p、miR-486-5p miR-592、miR-21-5p、miR-7-5p、miR-183-3p、miR-3610
肺癌 miR-7641、miR-6788-3p、miR202-3p、miR-6808-3p、miR-433-3p miR-153-5p、miR-301a-5p、miR-33b-p、miR-592、miR-577
胃癌 miR-139-5p、miR-133b、miR-139-3p、miR-145-3p、miR-1-3p miR-21-5p、miR-3662、miR-25-5p、miR-135b-5p、miR-21-3p
结直肠癌 Let-7d-3p、miR-5196-3p、miR-4743-5p、miR-328-3p、miR-139-5p Let-7f-1-3p、miR-590-5p、miR-889-3p、miR-455-5p、miR-18a-5p
膀胱癌 miR-139-3p、miR-1-3p、miR-30a-3p、miR-383-5p、miR-133b Let-7f-2-3p、miR-183-3p、miR-33b-5p、miR-147b、miR-210-5p
肾癌 miR-891a-5b、miR-10b-5p、miR-184、miR-141-3p、miR-145-5p miR-21-5p、miR-7156-5p、miR-21-3p、miR-93-5p、miR-25-3p
表2  miRNA在不同肿瘤组织中的特异性表达谱
病毒类型 miRNA 拷贝数 靶器官 插入位置 肿瘤模型 参考文献
柯萨奇病毒
A21型		 miR-133、miR-206 2 肌肉 基因组的3'-UTR 骨髓瘤 [22]
miR-133、miR-206 2 肌肉 基因组的5'-UTR 黑色素瘤 [23]
柯萨奇病毒
B3型		 miR-375 3 胰腺 基因组的5'-UTR
和3'-UTR		 结直肠癌 [24]
miR-34a 4 胰腺 基因组的5'-UTR
和3'-UTR		 肺癌 [25]
miR-1、miR-216、
miR-143、miR-145		 2~4 心脏、肌肉、胰腺 基因组的5'-UTR 乳腺癌 [26]
门戈病毒 miR-124、miR-133b、
miR-208a		 2 神经、心脏 基因组的5'-UTR
和3'-UTR		 浆细胞瘤 [27]
森林脑炎病毒 miR-124 6 神经 nsp3和nsp4之间 神经胶质瘤 [30]
麻疹病毒 miR-122、miR-7、miR-148a 3 神经、肝脏、胃肠 H和F的3'-UTR 胰腺癌 [33]
miR-124-3p、miR-125-5p、
miR-7-5p		 3~6 神经 N、F、H和L的
3'-UTR		 - [34]
miR-148a 3 胃肠 F的3'-UTR 胰腺癌 [35]
水泡性口炎病毒 Let-7 3 神经 M的3'-UTR 黑色素瘤 [40]
miR-125b 4 神经 L的3'-UTR 结直肠癌 [41]
腺病毒 miR-122 3 肝脏 E1A的3'-UTR - [44]
miR-148a、miR-216a 4~8 胰腺、肝脏 E1A的3'-UTR 胰腺癌 [45]
单纯疱疹病毒 miR-124-3p、miR-128-3p、
miR-137-3p、miR-204-5p、
miR-219a-5p、miR-1-3p、
miR-143-3p、miR-122-5p、
miR-126-3p、miR-217-5p		 3 神经、心脏、肝脏、
胰腺		 ICP4、ICP27、
UL8、ICP34.5的
3'-UTR		 结直肠癌、
黑色素瘤		 [48]
表3  miRNA去靶向的溶瘤病毒
病毒类型 miRNA 靶基因 作用效果 肿瘤模型 参考文献
腺病毒 miR-26b NF-κB 促进病毒复制 前列腺癌 [53]
miR-99b、miR-485 ELF4、MDM2、
KLF8		 促进病毒复制 胰腺导管腺癌 [54]
miR-222海绵 miR-222 增强病毒复制
与细胞毒性		 胰腺导管腺癌 [56]
水泡性口炎病毒 amiR-4 ARID1A 抑制干扰素通路,
提升溶瘤效果		 胰腺导管腺癌、
黑色素瘤		 [55]
表4  表达miRNA增强抗肿瘤作用的溶瘤病毒
[1] Bartel D P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
doi: 10.1016/j.cell.2009.01.002 pmid: 19167326
[2] Shang R F, Lee S, Senavirathne G, et al. MicroRNAs in action: biogenesis, function and regulation. Nature Reviews Genetics, 2023, 24(12): 816-833.
doi: 10.1038/s41576-023-00611-y
[3] Lee R C, Feinbaum R L, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5): 843-854.
doi: 10.1016/0092-8674(93)90529-y pmid: 8252621
[4] Lee R C, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science, 2001, 294(5543): 862-864.
doi: 10.1126/science.1065329 pmid: 11679672
[5] Liu H Y, Lei C, He Q, et al. Nuclear functions of mammalian microRNAs in gene regulation, immunity and cancer. Molecular Cancer, 2018, 17(1): 64.
doi: 10.1186/s12943-018-0765-5 pmid: 29471827
[6] Daugaard I, Hansen T B. Biogenesis and function of ago-associated RNAs. Trends in Genetics, 2017, 33(3): 208-219.
doi: S0168-9525(17)30003-3 pmid: 28174021
[7] Béthune J, Artus-Revel C G, Filipowicz W. Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells. EMBO Reports, 2012, 13(8): 716-723.
doi: 10.1038/embor.2012.82 pmid: 22677978
[8] Kozomara A, Griffiths-Jones S. MiRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Research, 2011, 39(Database issue): D152-D157.
[9] Kozomara A, Griffiths-Jones S. MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research, 2014, 42(D1): D68-D73.
doi: 10.1093/nar/gkt1181
[10] Boehm M, Slack F J. MicroRNA control of lifespan and metabolism. Cell Cycle, 2006, 5(8): 837-840.
doi: 10.4161/cc.5.8.2688 pmid: 16627994
[11] Fabian M R, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annual Review of Biochemistry, 2010, 79: 351-379.
doi: 10.1146/annurev-biochem-060308-103103 pmid: 20533884
[12] Ye Q, Raese R A, Luo D J, et al. MicroRNA-based discovery of biomarkers, therapeutic targets, and repositioning drugs for breast cancer. Cells, 2023, 12(14): 1917.
doi: 10.3390/cells12141917
[13] Chang T C, Yu D N, Lee Y S, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40(1): 43-50.
doi: 10.1038/ng.2007.30
[14] Lu J, Getz G, Miska E A, et al. MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043): 834-838.
doi: 10.1038/nature03702
[15] Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Science Signaling, 2015, 8(368): e2005825.
[16] Kavakiotis I, Alexiou A, Tastsoglou S, et al. DIANA-miTED: a microRNA tissue expression database. Nucleic Acids Research, 2022, 50(D1): D1055-D1061.
[17] Xu F, Wang Y F, Ling Y C, et al. DbDEMC 3.0: functional exploration of differentially expressed miRNAs in cancers of human and model organisms. Genomics, Proteomics & Bioinformatics, 2022, 20(3): 446-454.
[18] Kaufman H L, Kohlhapp F J, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 2015, 14(9): 642-662.
doi: 10.1038/nrd4663 pmid: 26323545
[19] Brown B D, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nature Biotechnology, 2007, 25(12): 1457-1467.
doi: 10.1038/nbt1372 pmid: 18026085
[20] Geisler A, Hazini A, Heimann L, et al. Coxsackievirus B3-its potential as an oncolytic virus. Viruses, 2021, 13(5): 718.
doi: 10.3390/v13050718
[21] Nekoua M P, Alidjinou E K, Hober D. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology, 2022, 18(8): 503-516.
doi: 10.1038/s41574-022-00688-1 pmid: 35650334
[22] Kelly E J, Hadac E M, Greiner S, et al. Engineering microRNA responsiveness to decrease virus pathogenicity. Nature Medicine, 2008, 14(11): 1278-1283.
doi: 10.1038/nm.1776 pmid: 18953352
[23] Kelly E J, Hadac E M, Cullen B R, et al. MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathogens, 2010, 6(3): e1000820.
doi: 10.1371/journal.ppat.1000820
[24] Pryshliak M, Hazini A, Knoch K, et al. MiR-375-mediated suppression of engineered coxsackievirus B 3 in pancreatic cells. FEBS Letters, 2020, 594(4): 763-775.
doi: 10.1002/1873-3468.13647 pmid: 31643074
[25] Jia Y, Miyamoto S, Soda Y, et al. Extremely low organ toxicity and strong antitumor activity of miR-34-regulated oncolytic coxsackievirus B3. Molecular Therapy-Oncolytics, 2019, 12: 246-258.
doi: 10.1016/j.omto.2019.01.003 pmid: 30891489
[26] Bahreyni A, Liu H T, Mohamud Y, et al. A new miRNA-modified coxsackievirus B 3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice. Cancer Letters, 2022, 548: 215849.
doi: 10.1016/j.canlet.2022.215849
[27] Ruiz A J, Hadac E M, Nace R A, et al. MicroRNA-detargeted mengovirus for oncolytic virotherapy. Journal of Virology, 2016, 90(8): 4078-4092.
doi: 10.1128/JVI.02810-15 pmid: 26865716
[28] Penza V, Maroun J W, Nace R A, et al. Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model. Molecular Therapy-Oncolytics, 2023, 28: 15-30.
doi: 10.1016/j.omto.2022.11.006
[29] Heikkilä J E, Vähä-Koskela M J V, Ruotsalainen J J, et al. Intravenously administered alphavirus vector VA 7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One, 2010, 5(1): e8603.
doi: 10.1371/journal.pone.0008603
[30] Ylösmäki E, Martikainen M, Hinkkanen A, et al. Attenuation of semliki forest virus neurovirulence by microRNA-mediated detargeting. Journal of Virology, 2013, 87(1): 335-344.
doi: 10.1128/JVI.01940-12 pmid: 23077310
[31] Laksono B M, de Vries R D, Duprex W P, et al. Measles pathogenesis, immune suppression and animal models. Current Opinion in Virology, 2020, 41: 31-37.
doi: S1879-6257(20)30011-0 pmid: 32339942
[32] Dispenzieri A, Tong C, LaPlant B, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia, 2017, 31(12): 2791-2798.
doi: 10.1038/leu.2017.120 pmid: 28439108
[33] Baertsch M A, Leber M F, Bossow S, et al. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Therapy, 2014, 21(9): 373-380.
doi: 10.1038/cgt.2014.40 pmid: 25145311
[34] Leber M F, Baertsch M A, Anker S C, et al. Enhanced control of oncolytic measles virus using microRNA target sites. Molecular Therapy-Oncolytics, 2018, 9: 30-40.
doi: 10.1016/j.omto.2018.04.002 pmid: 29988512
[35] Singh H M, Leber M F, Bossow S, et al. MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Molecular Therapy-Oncolytics, 2021, 21: 340-355.
doi: 10.1016/j.omto.2021.04.015 pmid: 34141871
[36] Drolet B S, Stuart M A, Derner J D. Infection of Melanoplus sanguinipes grasshoppers following ingestion of rangeland plant species harboring vesicular stomatitis virus. Applied and Environmental Microbiology, 2009, 75(10): 3029-3033.
doi: 10.1128/AEM.02368-08
[37] Stojdl D F, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine, 2000, 6(7): 821-825.
doi: 10.1038/77558 pmid: 10888934
[38] Shinozaki K, Ebert O, Suriawinata A, et al. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. Journal of Virology, 2005, 79(21): 13705-13713.
pmid: 16227290
[39] Johnson J E, Nasar F, Coleman J W, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology, 2007, 360(1): 36-49.
doi: 10.1016/j.virol.2006.10.026 pmid: 17098273
[40] Edge R E, Falls T J, Brown C W, et al. A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Molecular Therapy, 2008, 16(8): 1437-1443.
doi: 10.1038/mt.2008.130 pmid: 18560417
[41] Kelly E J, Nace R, Barber G N, et al. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. Journal of Virology, 2010, 84(3): 1550-1562.
doi: 10.1128/JVI.01788-09 pmid: 19906911
[42] 中国临床肿瘤学会免疫治疗专家委员会, 上海市抗癌协会肿瘤生物治疗专业委员会. 基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识(2022年版). 中国癌症杂志, 2023, 33(5): 527-550.
doi: 10.19401/j.cnki.1007-3639.2023.05.013
Chinese Society of Clinical Oncology Immunotherapy Expert Committee, Shanghai Anti-Cancer Association Tumor Biological Therapy Professional Committee. Chinese expert consensus on the clinical application of genetically recombinant oncolytic adenovirus in the treatment of malignant tumors (2022 edition). Chinese Journal of Cancer, 2023, 33(5): 527-50.
doi: 10.19401/j.cnki.1007-3639.2023.05.013
[43] 杨豪, 张绍庚, 杨鹏辉. 溶瘤病毒的免疫学机制及临床研究进展. 生物化学与生物物理进展, 2022, 49(8): 1398-1405.
Yang H, Zhang S G, Yang P H. Immunologic mechanisms and clinical research progress of oncolytic viruses. Progress in Biochemistry and Biophysics, 2022, 49(8): 1398-1405.
[44] Ylösmäki E, Hakkarainen T, Hemminki A, et al. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific microRNA. Journal of Virology, 2008, 82(22): 11009-11015.
doi: 10.1128/JVI.01608-08 pmid: 18799589
[45] Bofill-De Ros X, Gironella M, Fillat C. MiR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity. Molecular Therapy, 2014, 22(9): 1665-1677.
doi: 10.1038/mt.2014.98 pmid: 24895996
[46] Dai M H, Zamarin D, Gao S P, et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. The British Journal of Srugery, 2010, 97(9): 1385-1394.
[47] Eager R M, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Therapy, 2011, 18(5): 305-317.
doi: 10.1038/cgt.2011.7 pmid: 21436867
[48] Kennedy E M, Farkaly T, Grzesik P, et al. Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability. Molecular Therapy-Oncolytics, 2020, 18: 476-490.
doi: 10.1016/j.omto.2020.08.004 pmid: 32953982
[49] Doench J G, Petersen C P, Sharp P A. SiRNAs can function as miRNAs. Genes & Development, 2003, 17(4): 438-442.
doi: 10.1101/gad.1064703
[50] Sætrom P, Heale B S E, Snøve O, et al. Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Research, 2007, 35(7): 2333-2342.
pmid: 17389647
[51] Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition. Nature Genetics, 2007, 39(10): 1278-1284.
doi: 10.1038/ng2135 pmid: 17893677
[52] Long D, Lee R, Williams P, et al. Potent effect of target structure on microRNA function. Nature Structural & Molecular Biology, 2007, 14(4): 287-294.
doi: 10.1038/nsmb1226
[53] Hodzic J, Sie D, Vermeulen A, et al. Functional screening identifies human miRNAs that modulate adenovirus propagation in prostate cancer cells. Human Gene Therapy, 2017, 28(9): 766-780.
doi: 10.1089/hum.2016.143
[54] Rovira-Rigau M, Raimondi G, Marín M Á, et al. Bioselection reveals miR-99b and miR-485 as enhancers of adenoviral oncolysis in pancreatic cancer. Molecular Therapy, 2019, 27(1): 230-243.
doi: S1525-0016(18)30457-X pmid: 30341009
[55] Wedge M E, Jennings V A, Crupi M J F, et al. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nature Communications, 2022, 13(1): 1898.
doi: 10.1038/s41467-022-29526-8
[56] Raimondi G, Gea-Sorlí S, Otero-Mateo M, et al. Inhibition of miR-222 by oncolytic adenovirus-encoded miRNA sponges promotes viral oncolysis and elicits antitumor effects in pancreatic cancer models. Cancers, 2021, 13(13): 3233.
doi: 10.3390/cancers13133233
[1] 韩佳, 范月蕾, 毛开云. 溶瘤病毒市场及研发格局分析*[J]. 中国生物工程杂志, 2023, 43(6): 87-101.
[2] 邓思雨, 梁冰, 魏薇, 王孟娜, 曹友德. miR-34a-5p对三阴性乳腺癌细胞的影响及相关机制研究*[J]. 中国生物工程杂志, 2023, 43(1): 18-26.
[3] 张保惠,熊华龙,张天英,袁权. 基于水疱性口炎病毒(VSV)的溶瘤病毒研究进展 *[J]. 中国生物工程杂志, 2020, 40(6): 53-62.
[4] 张潘红,李莲莲,张秀美,崔家骏,姜银杰. microRNA对肺癌化疗耐药性影响的研究进展 *[J]. 中国生物工程杂志, 2019, 39(7): 79-84.
[5] 沈冰蕾,王宇轩,韩硕,李熹,杨卓妮娜,邹紫雯,刘娟. 非编码RNA在细胞自噬中的研究进展 *[J]. 中国生物工程杂志, 2019, 39(12): 56-63.
[6] 刘怡萱, 边珍, 马红梅. 癌症基因治疗技术进展与展望[J]. 中国生物工程杂志, 2016, 36(5): 106-111.
[7] 罗嘉, 沈林園, 李强, 李学伟, 张顺华, 朱砺. 哺乳动物中作用于非编码RNA的RNA编辑研究进展[J]. 中国生物工程杂志, 2016, 36(11): 76-82.
[8] 辛婧, 徐银胜, 张芳, 盛望. MicroRNA-124对人宫颈癌的抑制作用及机制研究[J]. 中国生物工程杂志, 2015, 35(10): 13-19.
[9] 满朝来, 唐高霞, 赵丽, 李凤, 甄鑫. DNA甲基化与microRNA[J]. 中国生物工程杂志, 2014, 34(8): 81-87.
[10] 满朝来, 常杨, 唐高霞, 赵丽, 李凤, 甄鑫, 弭晓菊. 基因佐剂的研究进展[J]. 中国生物工程杂志, 2013, 33(7): 112-117.
[11] 董园园, 李海燕, 李校堃, 杨树林. 红花microRNAs靶基因的生物信息学预测[J]. 中国生物工程杂志, 2012, 32(10): 33-38.
[12] 唐德平, 毛爱红, 廖世奇, 薛林贵, 张柄林. siRNA脱靶效应类型与规避策略[J]. 中国生物工程杂志, 2012, 32(07): 113-119.
[13] 申健, 张越, 潘秋辉, 孙奋勇. 生物信息学分析及预测miR-17-92的分子调控网络[J]. 中国生物工程杂志, 2012, 32(03): 69-75.
[14] 王启钊 吕颖慧 肖卫东 刁勇 许瑞安. 重组腺相关病毒载体临床实验研究[J]. 中国生物工程杂志, 2010, 30(01): 73-79.
[15] 曹孙琼,任常山. 靶向NBS1基因的 microRNA真核表达载体的构建及其活性鉴定[J]. 中国生物工程杂志, 2008, 28(4): 7-11.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会